Ignite Creation Date:
2024-05-06 @ 5:53 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05469178
Status:
RECRUITING
Last Update Posted:
2023-10-10
First Post:
2022-07-19
Brief Title:
A Study to Investigate the Safety Tolerability and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
Sponsor:
BerGenBio ASA
Organization:
BerGenBio ASA
Organization Data
Organization:
BerGenBio ASA
Class:
INDUSTRY
Study ID:
BGBC016
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
BerGenBio ASA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None